Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3CNS 1

Conditions

Neuroblastoma 44Ganglioneuroblastoma 6Brain Neoplasms 6Sarcoma 5Neoplasms 5Glioma 5Glioblastoma 5Central Nervous System Neoplasms 3Astrocytoma 3Optic Nerve Glioma 2Oligodendroglioma 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Breast Neoplasms 2Bone Neoplasms 2Wilms Tumor 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neurofibromatosis 1 1

Interventions

Docetaxel 6Radiotherapy 5Filgrastim 3Erlotinib Hydrochloride 3Cetuximab 3Capecitabine 3Bevacizumab 3entrectinib 2Radiotherapy, Intensity-Modulated 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Gemcitabine 2Fluorodeoxyglucose F18 2Cisplatin 2Chemotherapy, Adjuvant 2Acupuncture Therapy 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1tanespimycin 1spartalizumab 1sargramostim 1oncogene protein E7, Human papillomavirus type 16 1entinostat 1cevimeline 1alectinib 1aldesleukin 1X-Ray Therapy 1Vorinostat 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × Doxorubicin × CNS × Clear all
NCT00509665 2018-07-12

Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer

Medical University of South Carolina

Phase 2 Completed
18 enrolled 9 charts
CNSHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡